SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

NCT06122389 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Interventions

DRUG: SHR2554; Chidamide analog tablets
DRUG: SHR2554 analog tablets; Chidamide

Sponsor

Jiangsu HengRui Medicine Co., Ltd.